AstraZeneca settles Nexium and Prilosec product liability litigations

AstraZeneca plc (LON:AZN) has entered into settlement agreements in the product liability litigations related to Nexium and Prilosec. The agreements effectively resolve the product liability claims that are currently pending in the Multidistrict Litigation in the US District Court for the District of New Jersey, as well as in the Delaware Superior Court and the New Jersey Superior Court. The specific terms of the agreements are confidential.

AstraZeneca continues to believe these claims are without merit and admits no wrongdoing in the settlement agreement. These settlements avoid continued costly litigation and allow the Company to move forward with its purpose of delivering life changing medicines to millions of patients around the world.

A single case remains pending in the US District Court for the Middle District of Louisiana. Trial is scheduled in that case for April 15, 2024.

Financial considerations
AstraZeneca will make payment of $425 million, for which a provision has been taken.

Share on:

Written by: Amilia Stone

Latest Company News

AstraZeneca’s Etcamah approved in US for ESR1-mutated advanced breast cancer

September 7, 2026

The FDA has approved Etcamah (camizestrant) with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer after detection of an emerging ESR1 mutation, based on Phase III SERENA-6 results showing a 56% reduction in the risk of disease progression or death.

AstraZeneca’s Tezspire meets key endpoints in Phase III EoE trial

August 27, 2026

AstraZeneca has reported positive Phase III CROSSING trial results for Tezspire in eosinophilic oesophagitis, with benefits sustained to week 52.

AstraZeneca strengthens funding position with €2.55 billion Eurobond issue

August 25, 2026

AstraZeneca has priced four tranches of Eurobonds totalling €2.55 billion, with closing expected on 1 September 2026.

AstraZeneca reports positive Phase III results for Tagrisso-Orpathys lung cancer combination

August 17, 2026

Astrazeneca Plc has reported positive SAFFRON Phase III results for Tagrisso and Orpathys, showing improved progression-free and overall survival.

AstraZeneca H1 2026 revenue rises 9% as growth momentum continues

July 27, 2026

AstraZeneca reported first-half 2026 revenue of $30.7 billion, up 6% at constant exchange rates, with core operating profit and core EPS both rising 11%. Growth in oncology and rare disease offset Farxiga and China headwinds. The company raised its interim dividend, secured 30 approvals, and reaffirmed full-year guidance and its $80 billion 2030 revenue goal.